35 results match your criteria: "Sezione Clinica[Affiliation]"
Clin Sci (Lond)
May 1994
Dipartimento di Medicina Interna, Sezione Clinica Medica I, Pavia, Italy.
1. Although the high-frequency fluctuations in R-R interval (respiratory sinus arrhythmia) observed in heart transplant recipients are not a reliable marker of reinnervation because of a previously shown direct mechanical effect of breathing, the presence of a non-respiration-related low-frequency oscillation reflects rhythms generated outside the heart, and thus could be neurally mediated. 2.
View Article and Find Full Text PDFFolia Biol (Praha)
December 1994
Dipartimento di Scienze Biomediche ed Oncologia Umana, Sezione Clinica, University of Torino.
Over the last few years the possibility of introducing foreign material into the genome of host cells has become technically feasible. This has opened a new era in the treatment of congenital disorders, but has also offered potential innovative avenues in the management of cancer patients. Here, we shall discuss how cytokine genes may be successfully transduced into the DNA of different experimental tumours and how through this approach the tumorigenicity of the neoplastic cells may be abrogated.
View Article and Find Full Text PDFInt J Clin Lab Res
June 1994
Dipartimento di Scienze Biomediche e Oncologia Umana, Sezione Clinica, Turin, Italy.
Taxol (paclitaxel), an anti-microtubule agent extracted from the needles and bark of the Pacific yew tree Taxus brevifolia, has shown a remarkable anti-neoplastic effect in human cancer in phase I studies and early phase II and III trials thus far conducted. This has been reported primarily in advanced ovarian and breast cancer, although significant activity has also been documented in small-cell and non-small-cell lung cancer, head and neck cancers, and with lower activity in metastatic melanoma. The clinical utilization of Taxol had been previously somewhat restricted by its limited availability, a limitation that has recently been overcome by combined efforts of pharmaceutical, agricultural, and governmental agencies.
View Article and Find Full Text PDFLeukemia
February 1992
Dipartimento di Scienze Biomediche e Oncologia Umana, Sezione Clinica, Torino, Italy.
Different normal and malignant human B-cell populations were studied with a twofold aim: to define which cytokines are produced in vivo, and to assess the relationship between cytokine production and kinetic state. To analyse normal B-cells representative of different stages of activation and proliferation in vivo, we purified germinal centre (GC)-B blasts and mantle B (M-B) cells from tonsils. To compare malignant B lymphocytes with their closest normal equivalent cells, we separated malignant CD5+B lymphocytes from the peripheral blood of patients with B-chronic lymphocytic leukemia (B-CLL) and normal CD5+B lymphocytes from cord blood.
View Article and Find Full Text PDFLeukemia
December 1991
Dipartimento di Scienze Biomediche e Oncologia Umana, Sezione Clinica, University of Torino, Italy.
An identical extra derivative chromosome resulting from a translocation between the long arm of chromosome 1 and the short arm of chromosome 9, +der(1q9p), has been observed in three patients with a myeloproliferative disorder. Two patients had polycythemia vera in transformation (erythroleukemia in one patient and refractory anemia in the second), whereas the third patient had myelofibrosis which later evolved into acute myelomonocytic leukemia. The two patients who developed overt leukemia did not receive any previous cytotoxic treatment.
View Article and Find Full Text PDFBlood
June 1991
Departimento di Scienze Biomediche e Oncologia Umana,Sezione Clinica and Sezione di Istologia, Università di Torino, Italy.
We have verified the hypothesis that multiple myeloma (MM) may be disseminated by circulating clonogenic cells that selectively home to the bone marrow (BM) to receive the signal(s) leading to proliferation, terminal differentiation, and production of the osteoclast activating factors. Long-term cultures of stromal cells have been developed from the BM of nine patients with MM. These cells were mostly fibroblast-like elements, interspersed with a proportion of scattered macrophages and rare osteoclasts.
View Article and Find Full Text PDFLeuk Lymphoma
July 2016
a Dipartimento di Scienze Biomediche ed Oncologia Umana, Sezione Clinica and Centro CNR "Immunogenetica ed Istocompatibilita", University of Torino, Italy.
We hereby here the successful use of a combined therapeutic approach with alpha 2b Interferon (IFN) and Chlorambucil in the management of previously treated B-cell chronic lymphocytic leukemia (B-CLL). The two patients under study had been managed with repeated and frequent cycles of Chlorambucil. Rather than with more toxic multidrug regimens, the hematological picture was controlled with 3 MU of IFN every three-five days and 5 mg of Chlorambucil every two-five days.
View Article and Find Full Text PDFHaematologica
April 1991
Dipartimento di Medicina Interna e Terapia Medica, Sezione Clinica Medica 2, IRCCS Policlinico S. Matteo, Pavia.
Blut
June 1989
Dipartimento di Medicina Interna e Terapia Medica, Sezione Clinica Medica 2, IRCCS Policlinico S. Matteo, Pavia, Italy.
In an attempt to reduce myeloproliferation, we administered recombinant alpha-2b interferon (r-alpha INF) to ten patients with myelofibrosis with myeloid metaplasia (MMM) in a hypercellular phase, as part of a phase II trial. Two patients experienced severe side effects and stopped treatment before completion of the first week. In the eight evaluable patients, r-alpha INF was given for 16 weeks at an initial dosage of 3 X 10(6) U/day, with monthly increments in the case of response failure, i.
View Article and Find Full Text PDFActa Haematol
November 1989
Dipartimento di Medicina Internae e Terapia Medica, Sezione Clinica Medica II, IRCCS Policlinico S. Matteo, Pavia, Italia.
We report a male patient in whom a diagnosis of essential thrombocythaemia was made at the age of 25. The clinical course was characterised by recurrent thrombotic episodes during the first few years of the disease, followed by a relatively benign course. He was treated with 32P, nitrogen mustard and plateletpheresis.
View Article and Find Full Text PDF